Completed PHASE3 INTERVENTIONAL 2-arm NCT00339183

Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone

A Randomized, Multicenter Phase 3 Study to Compare the Efficacy of Panitumumab in Combination With Chemotherapy to the Efficacy of Chemotherapy Alone in Patients With Previously Treated Metastatic Colorectal Cancer

Sponsor: Amgen

Conditions Metastatic Colorectal Cancer

Interventions FOLFIRI Panitumumab

Updated 7 times since 2017 Last updated: Sep 12, 2022 Started: Jun 30, 2006 Primary completion: Apr 1, 2009 Completion: Nov 1, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Metastatic Colorectal Cancer and is currently completed. Amgen leads this study, which shows 7 recorded versions since 2006 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Sep 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Sep 2022 [monthly]

Completed PHASE3
Sep 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Sep 2018 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jun 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amgen

Data source: Amgen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.